Lv3
203 积分 2021-07-14 加入
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
2天前
已完结
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
2天前
已完结
Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma
12天前
已完结
Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma
13天前
已完结
SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions
13天前
已完结
Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma
3个月前
已完结
Outcomes With First‐Line PD1 Inhibitors in Extranodal NK/T‐Cell Lymphoma: A Comparative Analysis From a 755‐Patient Multicenter Cohort
3个月前
已关闭
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
3个月前
已完结
Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation
4个月前
已完结
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
4个月前
已完结
皖公网安备34019202002308
